Basit öğe kaydını göster

dc.contributor.authorFeyizoglu, Gunes
dc.contributor.authorOguz, Aytekin
dc.contributor.authorCaklili, Ozge Telci
dc.contributor.authorGul, Zeynep
dc.contributor.authorKarsli, Asli
dc.contributor.authorKeskinler, Mirac Vural
dc.contributor.authorBozkurt, Irem
dc.date.accessioned2021-12-10T10:06:21Z
dc.date.available2021-12-10T10:06:21Z
dc.date.issued2021
dc.identifier.citationKeskinler M. V. , Bozkurt I., Caklili O. T. , Feyizoglu G., Gul Z., Karsli A., Oguz A., "COMPARISON OF REAL WORLD LIPID PROFILE OF PATIENTS WITH TYPE 2 DIABETES AND GUIDELINE RECOMMENDATIONS", ACTA CLINICA CROATICA, cilt.60, sa.1, ss.63-67, 2021
dc.identifier.issn0353-9466
dc.identifier.othervv_1032021
dc.identifier.otherav_293f0b29-bd05-4309-a014-e32830f89bd7
dc.identifier.urihttp://hdl.handle.net/20.500.12627/169200
dc.identifier.urihttps://doi.org/10.20471/acc.2021.60.01.09
dc.description.abstractDiabetes is a major risk factor for cardiovascular disease. Despite recommendations and available therapeutic options, patients with diabetes do not always reach the recommended lipid levels. In this study, our aim was to compare the real world lipid profile of type 2 diabetes patients with guideline recommendations for dyslipidemia. Four hundred and sixty eight consecutive patients referred to Outpatient Diabetes Clinic of Istanbul Medeniyet University were recruited. Patient anthropometric measurements (height, weight, waist circumference), biochemical test results (LDL cholesterol (LDL-c), triglycerides, HDL cholesterol, HbA1c) and treatment modalities were recorded. Patients were stratified into cardiovascular risk categories according to the risk factors and their treatment dose was compared to the recommendations. Among 468 patients, 56 (12%) patients had coronary heart disease (CHD). Thirty-four percent of these patients were not on statin treatment (n=19) and their mean LDL-c level was 114 +/- 29 mg/dL (2.9 +/- 0.75 mmol/L). Nineteen percent of these patients were on high intensity statin treatment (atorvastatin 40-80 mg, rosuvastatin 20 mg). Only four patients with CHD had LDL-c levels <70 mg/dL (1.8 mmol/L). Four hundred and twelve patients had no CHD. In these patients, the mean LDL-c level was 132 +/- 38 mg/dL (3.4 +/- 0.9 mmol/L). Eighty (19%) patients had LDL-c level lower than 100 mg/dL (2.5 mmol/L). Overall 82% (n=384) of the cohort had not achieved treatment goal. In conclusion, a more pronounced approach for statin treatment is needed in diabetes patients for both primary and secondary prevention of cardiovascular diseases.
dc.language.isoeng
dc.subjectGeneral Health Professions
dc.subjectPathophysiology
dc.subjectInternal Medicine
dc.subjectAssessment and Diagnosis
dc.subjectMedicine (miscellaneous)
dc.subjectGeneral Medicine
dc.subjectHealth Sciences
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectFamily Practice
dc.subjectFundamentals and Skills
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, GENEL & İÇECEK
dc.titleCOMPARISON OF REAL WORLD LIPID PROFILE OF PATIENTS WITH TYPE 2 DIABETES AND GUIDELINE RECOMMENDATIONS
dc.typeMakale
dc.relation.journalACTA CLINICA CROATICA
dc.contributor.departmentIstanbul Goztepe Training and Research Hospital , ,
dc.identifier.volume60
dc.identifier.issue1
dc.identifier.startpage63
dc.identifier.endpage67
dc.contributor.firstauthorID2695968


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster